These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
366 related articles for article (PubMed ID: 2136814)
1. Biosynthesis and pharmacological modulation of thromboxane in humans. Patrono C Circulation; 1990 Jan; 81(1 Suppl):I12-5; discussion I22-3. PubMed ID: 2136814 [TBL] [Abstract][Full Text] [Related]
2. Pathophysiological role of thromboxane A2 and pharmacological approaches to its inhibition. Patscheke H; Hornberger W; Zehender H Z Kardiol; 1990; 79 Suppl 3():151-4. PubMed ID: 2099038 [TBL] [Abstract][Full Text] [Related]
3. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist. Vaghi F; Colombo M; Pierucci L; Volpi D; Dho L; Ukmar G; Rosa B; Salvati P Drugs Exp Clin Res; 1993; 19(6):249-60. PubMed ID: 8013268 [TBL] [Abstract][Full Text] [Related]
4. Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation. Vezza R; Nenci GG; Gresele P J Pharmacol Exp Ther; 1995 Dec; 275(3):1497-505. PubMed ID: 8531121 [TBL] [Abstract][Full Text] [Related]
5. Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism. Gresele P; Arnout J; Deckmyn H; Huybrechts E; Pieters G; Vermylen J J Clin Invest; 1987 Nov; 80(5):1435-45. PubMed ID: 2960694 [TBL] [Abstract][Full Text] [Related]
6. A comparative evaluation of thromboxane receptor blockade, thromboxane synthase inhibition and both in animal models of arterial thrombosis. Salvati P; Dho L; Ukmar G; Vaga L; Rimoldi O; Patrono C J Pharmacol Exp Ther; 1994 Apr; 269(1):238-45. PubMed ID: 8169831 [TBL] [Abstract][Full Text] [Related]
7. Ridogrel inhibits systemic and renal formation of thromboxane A2 and antagonizes platelet thromboxane A2/prostaglandin endoperoxide receptors upon chronic administration to man. Weber C; Beetens JR; Tegtmeier F; Van Rooy P; Vercammen E; Wouters L; De Clerck F Thromb Haemost; 1992 Aug; 68(2):214-20. PubMed ID: 1412169 [TBL] [Abstract][Full Text] [Related]
8. Characterization of thromboxane A2/prostaglandin H2 (TXA2/PGH2) receptors of rat platelets and their interaction with TXA2/PGH2 receptor antagonists. Hanasaki K; Arita H Biochem Pharmacol; 1988 Oct; 37(20):3923-9. PubMed ID: 2973322 [TBL] [Abstract][Full Text] [Related]
9. Preliminary clinical studies with thromboxane synthase inhibitors and thromboxane receptor blockers. A review. Fiddler GI; Lumley P Circulation; 1990 Jan; 81(1 Suppl):I69-78; discussion I79-80. PubMed ID: 2136820 [TBL] [Abstract][Full Text] [Related]
10. Binding of a thromboxane A2/prostaglandin H2 receptor antagonist to washed human platelets. Mais DE; Burch RM; Saussy DL; Kochel PJ; Halushka PV J Pharmacol Exp Ther; 1985 Dec; 235(3):729-34. PubMed ID: 3001275 [TBL] [Abstract][Full Text] [Related]
12. Pharmacologic characterization of human and canine thromboxane A2/prostaglandin H2 receptors in platelets and blood vessels: evidence for different receptors. Mais DE; Saussy DL; Chaikhouni A; Kochel PJ; Knapp DR; Hamanaka N; Halushka PV J Pharmacol Exp Ther; 1985 May; 233(2):418-24. PubMed ID: 2987481 [TBL] [Abstract][Full Text] [Related]
13. Antagonism of thromboxane A2/prostaglandin H2 by 13-azaprostanoic acid prevents platelet deposition to the de-endothelialized rabbit aorta in vivo. Le Breton GC; Lipowski JP; Feinberg H; Venton DL; Ho T; Wu KK J Pharmacol Exp Ther; 1984 Apr; 229(1):80-4. PubMed ID: 6423815 [TBL] [Abstract][Full Text] [Related]
14. 12-HETE inhibits the binding of PGH2/TXA2 receptor ligands in human platelets. Fonlupt P; Croset M; Lagarde M Thromb Res; 1991 Jul; 63(2):239-48. PubMed ID: 1837628 [TBL] [Abstract][Full Text] [Related]
15. Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis. Golino P; Rosolowsky M; Yao SK; McNatt J; De Clerck F; Buja LM; Willerson JT J Clin Invest; 1990 Oct; 86(4):1095-102. PubMed ID: 2145320 [TBL] [Abstract][Full Text] [Related]
17. Binding of an 125I-labeled thromboxane A2/prostaglandin H2 receptor antagonist to washed canine platelets. Mais DE; Kochel PJ; Saussy DL; Halushka PV Mol Pharmacol; 1985 Aug; 28(2):163-9. PubMed ID: 2991736 [TBL] [Abstract][Full Text] [Related]
18. Prostaglandin H2 in human platelet activation: coactivator and substitute for thromboxane A2. Hornberger WB; Patscheke H Prog Clin Biol Res; 1989; 301():315-9. PubMed ID: 2798452 [TBL] [Abstract][Full Text] [Related]
19. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--II. Pharmacological effects in vivo and ex vivo. De Clerck F; Beetens J; Van de Water A; Vercammen E; Janssen PA Thromb Haemost; 1989 Feb; 61(1):43-9. PubMed ID: 2526385 [TBL] [Abstract][Full Text] [Related]
20. Overview of physiological and pathophysiological effects of thromboxane A2. Ogletree ML Fed Proc; 1987 Jan; 46(1):133-8. PubMed ID: 2948837 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]